Insulet (NASDAQ: PODD) a diabetes-management firm in Bedford, MA, priced its secondary offering of 4.9 million shares at $23.25, according to an SEC filing. The shares were offered by Insulet shareholders, so no proceeds will go to the company.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
